天风证券研报指出,百济神州(688235.SH)第三季度经调整营业利润达6560万美元,连续两个季度实现非GAAP经营利润盈利。Q3核心品种泽布替尼美国区环比有增长,欧洲区保持环比快速增长。此外,2024年10月,替雷利珠单抗在中国新获批联合含铂化疗新辅助治疗、并在手术后继续本品单药辅助治疗NSCLC适应症。并在巴西、新加坡、泰国和以色列新获批NSCLC、ESCC等多个瘤种适应症。公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.